Short Interest in IPSEN (OTCMKTS:IPSEY) Expands By 286.5%

IPSEN (OTCMKTS:IPSEY) was the recipient of a significant increase in short interest during the month of June. As of June 15th, there was short interest totaling 143 shares, an increase of 286.5% from the May 31st total of 37 shares. Approximately 0.0% of the shares of the stock are short sold. Based on an average daily trading volume, of 568 shares, the days-to-cover ratio is presently 0.3 days.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on IPSEY shares. HC Wainwright began coverage on IPSEN in a report on Friday, June 5th. They issued a “buy” rating on the stock. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of IPSEN in a research note on Thursday, May 14th. Finally, Zacks Research raised IPSEN to a “hold” rating in a research report on Friday, May 29th. Two equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold”.

IPSEN Price Performance

Shares of IPSEY stock remained flat at $46.50 during trading hours on Friday. 42 shares of the stock were exchanged, compared to its average volume of 578. IPSEN has a twelve month low of $29.05 and a twelve month high of $51.10. The firm has a fifty day moving average of $47.34 and a two-hundred day moving average of $43.66.

About IPSEN

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).